C4 Therapeutics, Inc. Stock price

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2023-09-22 pm EDT Intraday chart for C4 Therapeutics, Inc. 5-day change 1st Jan Change
2.040 USD -6.85% -8.52% -65.42%
Sales 2023 * 19 M Sales 2024 * 22 M Capitalization 108 M
Net income 2023 * -148 M Net income 2024 * -189 M EV / Sales 2023 *
-9,84x
Net cash position 2023 * 291 M Net cash position 2024 * 204 M EV / Sales 2024 *
-4,42x
P/E ratio 2023 *
-0,80x
P/E ratio 2024 *
-0,80x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float92.20%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.90%
1 week-4.37%
Current month-24.48%
1 month-32.82%
3 months-26.01%
6 months-44.97%
Current year-62.88%
More quotes
1 week
2.05
Extreme 2.05
2.31
1 month
2.05
Extreme 2.05
3.43
Current year
2.05
Extreme 2.05
9.41
1 year
2.05
Extreme 2.05
10.42
3 years
2.05
Extreme 2.05
51.21
5 years
2.05
Extreme 2.05
51.21
10 years
2.05
Extreme 2.05
51.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 2020
Director of Finance/CFO 47 Sep. 17
Chief Tech/Sci/R&D Officer 56 2018
Members of the board TitleAgeSince
Chairman 75 -
Director/Board Member 66 2021
Director/Board Member 71 2015
More insiders
Date Price Change Volume
23-09-22 2.040 -6.85% 313 094
23-09-21 2.190 -0.90% 169,342
23-09-20 2.210  0.00% 212,197
23-09-19 2.210 +2.79% 342,523
23-09-18 2.150 -3.59% 2,342,226

Delayed Quote Nasdaq, September 21, 2023 at 04:00 pm EDT

More quotes
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.190USD
Average target price
19.00USD
Spread / Average Target
+767.58%
Consensus
  1. Markets
  2. Equities
  3. Stock C4 Therapeutics, Inc. - Nasdaq
-40% off #SeptemberDeals : Our subscriptions help you find hidden investment opportunities.
Subscribe
fermer